Clinical trial
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048 is registered in ClinicalTrials.gov with Corvus Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Lead sponsor
- Corvus Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 2, 2024
- Completion date
- December 31, 2028
- Enrollment
- 150 (estimated)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.
angioimmunoblastic t-cell lymphoma, follicular t-cell lymphoma, lymphoma, t-cell, lymphoma, t-cell, peripheral, nodal peripheral t-cell lymphoma with tfh phenotype, peripheral t-cell lymphoma, not otherwise specified, systemic anaplastic large cell lymphoma